Bortezomib represents the first proteasome inhibitor (PI) with demonstrated antitumor activity
in the clinical setting, particularly for treatment of hematological malignancies. At the …

Abstract Hypoxia-inducible factor (HIF-1) plays a central role in the cellular adaptive
response to hypoxic conditions, which are closely related to pathophysiological conditions …

Activation of hypoxia-inducible factor 1α (HIF1α) controls the transcription of genes
governing angiogenesis under hypoxic condition during tumorigenesis. Here we show that …

Abstract Bortezomib (PS-341), a proteasome inhibitor, has been examined clinically for the
treatment of multiple myeloma and several solid tumors. Bortezomib directly induces tumor …

Background Therapeutic targeting of the androgen signaling pathway is a mainstay
treatment for prostate cancer. Although initially effective, resistance to androgen targeted …

Purpose HIF1α over expression correlates with poor prognosis in a number of cancers.
Although it is widely accepted that hypoxia induces HIF1α expression up-regulation by a …

Recent studies provide strong evidence that the androgen receptor (AR) signaling pathway
remains active in castration-resistant prostate cancer (CRPC). However, the underlying …

Abstract Hypoxia-inducible factor 1 (HIF-1) is a heterodimeric transcription factorcomposed
of α and β subunits. HIF-1 is critically involved in cellular responses to hypoxia, glycolysis …

BACKGROUND Hypoxia-inducible factor-1α (HIF-1α) regulates cellular responses to
hypoxia and is rapidly degraded under normoxia through von Hippel-Lindau (VHL) …

Purpose: Androgen deprivation is implicated in reducing neoangiogenesis in prostate
cancer (PCA). Androgens regulate the expression of the vascular endothelial growth factor …